Note 12 - COMMITMENT	6 Months Ended
Jun. 30, 2011
Commitments Disclosure [Text Block]	Note 12 - COMMITMENT Research and Development (“R&D”) Agreement As of June 30, 2011, the Company entered into three agreements with certain research institutes to conduct clinical trials for three new drugs and one existing drug. Pursuant to these agreements as of June 30, 2011, the Company paid $1,294,677 as a deposit for clinical trial expenses and is obligated to pay the research institutes an additional $1,332,000 upon completion of the clinical trials. Capital commitments As of June 30, 2011, the Company had capital expenditure commitments on construction contracts, purchase of proprietary technologies and acquisition of business of approximately $25,800,000.

Note 12 - COMMITMENT

6 Months Ended

Jun. 30, 2011

Note 12 - COMMITMENT

Research and Development (“R&D”) Agreement

As of June 30, 2011, the Company entered into three agreements with certain research institutes to conduct clinical trials for three new drugs and one existing drug. Pursuant to these agreements as of June 30, 2011, the Company paid $1,294,677 as a deposit for clinical trial expenses and is obligated to pay the research institutes an additional $1,332,000 upon completion of the clinical trials.

Capital commitments

As of June 30, 2011, the Company had capital expenditure commitments on construction contracts, purchase of proprietary technologies and acquisition of business of approximately $25,800,000.

- Definition

The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.

+ References+ Details